[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600438":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":65,"collaborators":24,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":24,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":24,"enrollmentInfo":76,"targetDuration":24,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":89,"whyStopped":24,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Liposomal Bupivacaine","ACTIVE_COMPARATOR","randomized to liposomal bupivacaine in the adductor canal and infiltration between the popliteal artery and condyles of the knee (iPACK) block",[13],"Drug: Liposomal Bupivacaine",{"label":15,"type":10,"description":16,"interventionNames":17},"Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD)","randomized to bupivacaine mixed with clonidine, epinephrine, buprenorphine and dexamethasone in the adductor canal and infiltration between the popliteal artery and condyles of the knee (iPACK) block",[18],"Drug: Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","10 ml of 0.25% bupivacaine expanded with 133 mg (10 ml volume) of liposomal bupivacaine into both the adductor canal and iPACK blocks (total of 40 ml)",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination","20 ml of solution consisting of 0.25% bupivacaine, 1.667mcg\u002Fml of clonidine, 1:400,000 epinephrine, 0.15 mg total of buprenorphine, and 2 mg total of preservative free dexamethasone which will be used in both the adductor canal block and iPACK block (total of 40 ml)",[15],[30],{"name":31,"affiliation":32,"role":33},"Afua Gyamfi, MD","Atrium Health Wake Forest Baptist","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","336-716-4498","agyamfi@wakehealth.edu",{"name":40,"role":36,"phone":41,"phoneExt":41,"email":42},"Lynnette Harris, RN","336-716-8791","lynnette.harris@advocatehealth.org",[44],{"facility":32,"status":24,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Winston-Salem","North Carolina","27157","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-80.24422,36.09986,{"lat":54,"lon":53},[57,59,62,63],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":58},"agyuamfi@wakehealth.edu",{"name":60,"role":36,"phone":37,"phoneExt":24,"email":61},"James Turner, MD","jturner@wakehealth.edu",{"name":31,"role":33,"phone":24,"phoneExt":24,"email":24},{"name":60,"role":64,"phone":24,"phoneExt":24,"email":24},"SUB_INVESTIGATOR",{"type":66,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100600438","phase-4-liposomal-bupivacaine-vs-perineural-adjuvants-in-adductor-canalf-and-ipack-blocks-in-total-knee-arthroplasty-100600438",false,"NCT07097493","Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty","Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty","Inclusion Criteria:\n\n* 18-80 years of age\n* Receiving primary total knee arthroplasty\n* Patients receiving a spinal anesthetic with ropivacaine and fentanyl\n* American Society of Anesthesiology (ASA) category 1 to 3\n\nExclusion Criteria:\n\n* Revision of Total Knee Arthroplasty\n* Opioid use in the prior 6 months \\> 40 mg oxycodone equivalents per day or long-acting opioids as determined by the Prescription Drug Monitoring Program (PDMP)\n* Patients planned to receive general anesthesia\n* Patients planned to receive a spinal other than ropivacaine\n* History of peripheral neuropathy\n* Poorly controlled diabetes (Hgb A1C \\>8)\n* Allergies or contraindications to study medications: acetaminophen, celecoxib (including sulfa), methocarbamol, midazolam, fentanyl, bupivacaine, dexamethasone, acetaminophen, buprenorphine, NSAIDs, clonidine, epinephrine, and liposomal bupivacaine.\n* Unable to provide informed consent","ALL","18 Years",{"count":77,"type":78},90,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine, clonidine, epinephrine, buprenorphine, and dexamethasone. Pain scores will be collected at different intervals during study participation.",[84],"Knee Arthroplasty, Total",[86,87,88],"pain","knee surgery","pain management","NOT_YET_RECRUITING","2026-04-22",{"date":92,"type":93},"2026-04-23","ACTUAL",{"date":95,"type":78},"2026-08",{"date":97,"type":78},"2026-12-31",{"name":5,"class":6},1]